Department of Health and Social Care. HPV vaccine to be given to boys in England. 2018. (accessed 3 April 2018)

Mesher D, Panwar K, Thomas SL The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010–2016. J Infect Dis.. 2018; 218:(6)911-921

Patel C, Brotherton JML, Pillsbury A The impact of 10 years of human papilloma virus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Euro Surveill.. 2018; 23:(41)

Inequality and the HPV vaccine

11 April 2019
Volume 28 · Issue 7

The human papilloma virus (HPV) vaccine has resulted in an almost 90% reduction in the number of HPV infections in young women since 2010 (Mesher et al, 2018). Research has determined that the prevalence of HPV infections, which cause the majority of cervical cancers, fell by about 80% between 2010 and 2016 in women aged 16-18 years.

The provision of HPV vaccination for boys was secured at the end of July 2018 when the Government announced it would extend the use of the vaccine to boys aged 12-13 years (Department of Health and Social Care (DHSC), 2018)—a vaccine that can prevent HPV-related cervical, vaginal, penile, anal and oral cancers as well as genital warts. Vaccination has been offered to girls aged between 11 and 13 in England since 2008. Public Health England also carried out a catch-up programme for those girls aged 13-18 who had missed the vaccination. However, the public health minister, Steve Brine, has confirmed that there will be no such catch-up programme for boys. This decision is unacceptable.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content